

<p>Informazione Regolamentata n. 0957-17-2023</p>	<p>Data/Ora Ricezione 20 Aprile 2023 08:15:24</p>	<p>Euronext Milan</p>
---	---	-----------------------

Societa' : DIASORIN

Identificativo : 175543

Informazione  
Regolamentata

Nome utilizzatore : DIASORINN01 - Ulisse Spada - Valerio  
Giovanni Vaccarone

Tipologia : 2.5

Data/Ora Ricezione : 20 Aprile 2023 08:15:24

Data/Ora Inizio : 20 Aprile 2023 08:15:26

Diffusione presunta

Oggetto : Communication on total amount of voting  
rights

*Testo del comunicato*

See attachment.

## DIASORIN: COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS PURSUANT TO ARTICLE 85-BIS, PARAGRAPH 4-BIS, OF CONSOB REGULATION NO. 11971/1999

**Saluggia, April 20, 2023** – In accordance with Article 85-bis paragraph 4-bis, of Consob Regulation no. 11971/1999 DiaSorin (FTSE MIB: DIA) hereby communicates the total amount of the voting rights, together with the number of shares making up the share capital, as of April 19, 2023 (record date):

	Number of shares making up share capital	No. of voting rights	Euro
<b>Total amount, of which:</b>	55,948,257	88,332,271	55,948,257
<b>Ordinary shares without increased voting rights</b> ISIN IT0003492391 (regular dividend) Current coupon: no. 17	23,564,243	23,564,243	-
<b>Ordinary shares with increased voting rights</b> ISIN IT0005188385 (regular dividend) Current coupon: no. 17	32,384,014	64,768,028	-

### About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 41 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at [www.diasoringroup.com](http://www.diasoringroup.com)

### For additional information, please contact:

**Riccardo Fava**  
Corporate Vice President Communication & Investor Relations  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

**Eugenia Ragazzo**  
Corporate Investor Relations & ESG Analyst  
[eugenia.ragazzo@diasorin.it](mailto:eugenia.ragazzo@diasorin.it)

Fine Comunicato n.0957-17

Numero di Pagine: 3